PMV Pharmaceuticals, Inc. — Director's Dealing 2022

Feb 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2022-02-10

Reporting Person: Mack David Henry (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-10	Employee Stock Option (right to buy)	$16.29	A	249600	Acquired	2032-02-10	Common Stock (249600)	Direct

Footnotes

F1: Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.